Key Goals Met in Phase 3 Study
Ionis Pharmaceuticals announced on Tuesday that its olezarsen drug candidate has achieved key goals in a Phase 3 study involving familial chylomicronemia syndrome, a rare genetic disorder. With these positive results, the company is now set to move forward with planned regulatory filings.
Significant Reduction in Triglyceride Levels
The study demonstrated that the olezarsen 80-milligram monthly dose led to a statistically significant reduction in triglyceride levels compared to the placebo. Moreover, this triglyceride-lowering effect continued to improve even at the 12-month mark.
Dramatic Decrease in Acute Pancreatitis Events
Another noteworthy finding was that the olezarsen 80-milligram dose exhibited a 100% reduction in acute pancreatitis events compared to the placebo, which serves as a significant secondary endpoint for the study.
Seeking Regulatory Approval
Ionis Pharmaceuticals has announced its intention to file for approval from both the U.S. Food and Drug Administration and the European Union early next year. The approval of olezarsen would mark a significant milestone as it would become the first available treatment in the U.S. for familial chylomicronemia syndrome, a disorder that can lead to acute, potentially fatal pancreatitis attacks.
Our Latest News
SMIC, the largest China foundry specializing in chip manufacturing, faces challenges from geopolitical factors and supply chain uncertainties. Plunging profits,...
San Francisco City Attorney asks for halt to driverless robotaxis in the city due to safety concerns and risks posed to the public. Recent incidents highlight t...
Stock market timers have become extremely bearish, potentially indicating a buy opportunity. The sentiment has shifted from exuberance to bearishness, but timin...